Edesa Biotech Announces Upcoming Conference Schedule

Core Insights - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][2] - The company is participating in several upcoming conferences to enhance its business development efforts [1] Company Overview - Edesa Biotech is developing innovative treatments for inflammatory and immune-related diseases, with a clinical pipeline focused on Medical Dermatology and Respiratory therapeutic areas [2] - In Medical Dermatology, Edesa is advancing EB06, an anti-CXCL10 monoclonal antibody for vitiligo, and EB01, a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis [2] - The leading Respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome (ARDS) [2] - Edesa has received two funding awards from the Government of Canada to support the development of EB05 and is preparing an investigational new drug application for EB07 (paridiprubart) for a future Phase 2 study in pulmonary fibrosis [2]